Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists  by Scopinho, América A. et al.
Pharmacology, Biochemistry and Behavior 98 (2011) 268–272
Contents lists available at ScienceDirect
Pharmacology, Biochemistry and Behavior
j ourna l homepage: www.e lsev ie r.com/ locate /pharmbiochembehCannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A
receptor agonists
América A. Scopinho ⁎, Francisco S. Guimarães, Fernando M.A. Corrêa, Leonardo B.M. Resstel
Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, 14049-900 Ribeirão Preto, SP, BrazilAbbreviations: 2-AG, 2-arachidonoyl glycerol; CBD,
Δ9-THC, Δ9-tetrahydrocannabinol.
⁎ Corresponding author. Tel.: +55 16 36023207; fax:
E-mail address: americabiomed@yahoo.com.br (A.A
0091-3057/© 2011 Elsevier Inc. Open access under the Else
doi:10.1016/j.pbb.2011.01.007a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 August 2010
Received in revised form 1 December 2010
Accepted 8 January 2011





Serotoninergic systemΔ9-THC is a component of Cannabis sativa that increases food intake in animals and humans, an effect
prevented by selective CB1 receptor antagonists. Cannabidiol (CBD) is another constituent of this plant that
promotes several opposite neuropharmacological effects compared to Δ9-THC. CBD mechanisms of action are
still not clear, but under speciﬁc experimental conditions it can antagonize the effects of cannabinoid agonists,
block the reuptake of anandamide and act as an agonist of 5-HT1A receptors. Since both the cannabinoid and
serotoninergic systems have been implicated in food intake control, the aim of the present work was to
investigate the effects caused by CBD on hyperphagia induced by agonists of CB1 or 5-HT1A receptors. Fed or
fasted Wistar rats received intraperitoneal (i.p.) injections of CBD (1, 10 and 20 mg/kg) and food intake was
measured 30 min later for 1 h. Moreover, additional fed or fasted groups received, after pretreatment with
CBD (20 mg/kg) or vehicle, i.p. administration of vehicle, a CB1 receptor agonist WIN55,212-2 (2 mg/kg) or a
5-HT1A receptor agonist 8-OH-DPAT (1 mg/kg) and were submitted to the food intake test for 1 h. CBD by
itself did not change food intake in fed or fasted rats. However, it prevented the hyperphagic effects induced
by WIN55,212-2 or 8-OH-DPAT. These results show that CBD can interfere with food intake changes induced
by a CB1 or 5-HT1A receptor agonist, suggesting that its role as a possible food intake regulator should be
further investigate.Cannabidiol; 5-HT, serotonin;
+55 16 36022301.
. Scopinho).
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The regulation of food intake is a complex interplay between the
central nervous system (CNS) and the activity of several organs
involved in energy homeostasis. It is one component of energy
balance where endocrine signaling from the periphery to the CNS has
a particularly important role (Woods and D'Alessio, 2008). In the CNS
it involves several brain structures and effectors such as neuropep-
tides, monoamines, and the endocannabinoid system (Valassi et al.,
2008).
Δ9-Tetrahydrocannabinol (Δ9-THC) is the main component of the
Cannabis sativa plant, responsible for its behavioral effects as well as
increased hunger. Two cannabinoid receptors have now been
identiﬁed, named CB1 and CB2. The CB1 receptor is expressed mainly
in several brain areas involved in appetite regulation such as the
hypothalamus and nucleus accumbens, and peripherally in the liver,
gastrointestinal tract, pancreas, adipose tissue and skeletal muscle
(Di Marzo and Petrosino, 2007; Matias et al., 2008; Soria-Gomez et al.,
2007). The CB2 receptors are predominantly expressed in immune
cells such as monocytes, but are also present in the brain and cardiacmuscle (Cavuoto et al., 2007; Fernandez-Lopez et al., 2007; Pacher and
Ungvari, 2008).
The hyperphagic effect of Δ9-THC in rats is remarkably strong,
causing animals to overconsume even when they are fed (Williams
et al., 1998). This effect has been shown to be mediated by CB1
receptors, since it is reversed by the selective CB1 receptor antagonist
SR141716A (rimonabant), but not the selective CB2 antagonist
SR144258 (Williams and Kirkham, 2002). Similar CB1-mediated
hyperphagic effects have also been reported following administration
of the endocannabinoids anandamide and 2-arachidonoyl glycerol
(2-AG) (Gomez et al., 2002; Hao et al., 2000; Jamshidi and Taylor,
2001; Kirkham et al., 2002; Williams and Kirkham, 1999). Both
compounds are able to promote feeding when administered into
hypothalamic nuclei and into the shell of the nucleus accumbens
(Jamshidi and Taylor, 2001; Kirkham and Williams, 2001; Kirkham
et al., 2002), regions associatedwith eatingmotivation (Kirkham et al.,
2002; Schwartz et al., 2000). Moreover, acute or chronic administra-
tion of CB1 receptor antagonists such as rimonabant or AM251
suppresses food intake (Colombo et al., 1998; Vickers et al., 2003) and
reduces the consumption of palatable food in laboratory animals
(Gallate et al., 1999; Simiand et al., 1998). Together, these ﬁndings
support a key role for endocannabinoids in the control of eating.
Cannabidiol (CBD) is another constituent of C. sativa that may
constitute up to 40% of cannabis extracts (Grlie, 1976) and does not
cause the typical psychological effects of Δ9-THC (Zuardi et al., 1982).
Fig. 1. Effects of systemic injection of vehicle (n=5/group) or 1, 10 or 20 mg/kg of CBD
(n=5/group) on food intake (g) by fed or fasted rats. Columns represent themeans and
bars represent the SEM.
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(D'Souza et al., 2004) and may have anti-psychotic (Zuardi et al.,
2006), anxiolytic (Guimaraes et al., 1990; Resstel et al., 2006),
antidepressant (Zanelati et al., 2010) and neuroprotective (Hermann
et al., 2007) properties.
The mechanisms of CBD effects are not altogether clear. Although
it has a low afﬁnity for CB1 receptors (Petitet et al., 1998; Thomas
et al., 1998) it could antagonize the effects of cannabinoid agonists
(Pertwee et al., 2002; Zuardi et al., 1981). Moreover, CBD blocks the
reuptake of anandamide (Bisogno et al., 2001) and acts as an agonist
at 5-HT1A receptors (Resstel et al., 2009; Russo et al., 2005; Zanelati
et al., 2010). Central serotoninergic systems are also involved in the
regulation of eating behavior (Leibowitz, 1990; Leibowitz and
Alexander, 1998) and the 5-HT1A receptor agonist 8-OH-DPAT
induces hyperphagia in satiated rats (Dourish et al., 1985).
Therefore, based on these pieces of evidence, the present study
was aimed at investigating the effects of CBD on food intake changes
induced by CB1 and 5-HT1A receptor agonists.
2. Methods
2.1. Animal preparation
Male Wistar rats (n=120) weighing 230–270 g were used.
Animals were kept in the Animal Care Unit of the Department of
Pharmacology, School of Medicine of Ribeirão Preto, University of São
Paulo. Rats were housed in plastic cages under standard laboratory
conditions, under a 12-h light–dark cycle (lights on from 06:00 to
18:00 h), with free access to food and water (according to the
experiment). All experimental procedures were carried out during the
lights-on cycle. The institution's animal ethics committee approved
the animal housing conditions and experimental procedures.
2.2. Drug injections
The following drugs were used: CBD (THC Pharma, Frankfurt,
Germany, 1, 10 or 20 mg/kg), suspended in polyoxyethylenesorbitan
monooleate (Tween 80) 2%-saline (Resstel et al., 2006); 8-OH-DPAT
(Tocris, USA, 1 mg/kg, dose based on Hutson et al., 1988) and
WIN55,212-2 (Tocris, USA, 2 mg/kg, dose based on Merroun et al.,
2009), dissolved in sterile saline solution. The solutions were
prepared immediately before use and injected intraperitoneally in a
volume of 1 mL/kg. The appropriate vehicles were used in each
experiment.
2.3. Experimental protocol
2.3.1. Experiment 1—Effect of CBD on fed and fasted animals
One day before the test, the rats were divided into two groups:
animals that had access to food (fed) and 18 h food-deprived animals
(fasted) (Kittner et al., 2006; Scopinho et al., 2008). On the next day,
in the morning (between 7 and 12 a.m.), the animals were placed
individually in plastic cages (test cage) inside a soundproof room.
After 30 min of environmental adaptation, both groups of rats
received a single intraperitoneal (i.p.) injection of one of the following
drugs: vehicle (n=5) or CBD (1, 10 or 20 mg/kg, n=5 for each dose).
Thirty minutes later they were submitted to the food intake test
where a petri dish with previously weighed food pellets was placed in
the test cage. The food intake test lasted for 1 h, and the petri dish was
reweighed to calculate food intake. Food spillage on the cage ﬂoor was
also considered andweighed. Nowater was available during the trials.
2.3.2. Experiment 2—Effect of CBD on hyperphagia induced by
WIN55,212-2
One day before the test the animals were divided into two groups:
those that had access to food (fed) and 18 h food-deprived animals(fasted). On the next day, animals were tested after being submitted
to the previously described conditions of adaptation. The two groups
of animals were injected with CBD (20 mg/kg, n=5) or vehicle
(n=5). After 15 min they received WIN55,212-2 (2 mg/kg, n=5) or
vehicle (n=5) and 15 min later were submitted to the food intake
test, which lasted 1 h.2.3.3. Experiment 3—Effect of CBD on hyperphagia induced by
8-OH-DPAT
One day before the test the animals were divided into two groups:
those that had access to food (fed) and 18 h food-deprived animals
(fasted). On the next day, animals were tested after being submitted
to the previously described conditions of adaptation. The two groups
of animals were injected with CBD (20 mg/kg, n=5) or vehicle
(n=5). Fifteen minutes later they received 8-OH-DPAT (1 mg/kg,
n=5) or vehicle (n=5). Fifteen minutes after the last injection, the
animals were submitted to the food intake test, which lasted 1 h.2.4. Statistical analysis
The results were analyzed by a two-way ANOVA (factors:
treatment and condition). When indicated post-hoc analyses were
done using the Bonferroni test. Probability less than 0.05was accepted
as signiﬁcant.3. Results
3.1. Effect of CBD on fed and fasted animals
The amount of food ingested by fasted animals was signiﬁcantly
higher than fed animals (condition factor, F1,32=199, pb0.0001). CBD
did not change food intake in neither group (treatment factor
F3,32=0.09, pN0.05 and there was no interaction between factors
F3,32=1.3, pN0.05) (Fig. 1).3.2. Effect of CBD on hyperphagia induced by WIN55,212-2
CBD decreased the hyperphagia induced by WIN55,212-2 in both
fed and fasted rats (treatment factor F3,30=57.7, pb0.0001, interac-
tion between factors, F3,30=1.7, pN0.05) (Fig. 2).3.3. Effect of CBD on hyperphagia induced by 8-OH-DPAT
CBD decreased the hyperphagia induced by 8-OH-DPAT in both fed
and fasted rats (treatment factor F3,32=21.5, pb0.0001, interaction
between factors, F3,32=1.4, pN0.05) (Fig. 3).
Fig. 2. Effects of systemic injection of vehicle+vehicle (veh,n=4), vehicle+WIN55,212-2
(WIN, 2 mg/kg,n=5),CBD(20 mg/kg)+vehicle (n=5), CBD(20 mg/kg)+WIN(2 mg/kg,
n=5), on food intake (g) by fed or fasted rats. Columns represent the means and bars
represent the SEM, *pb0.0001 compared to respective vehicle+vehicle group; #pb0.0001
compared to respective vehicle+WIN group.
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Systemic administration of CBD caused no changes in food intake
in either fed or fasted rats. This result is in agreement with the
ﬁndings of Wiley et al. (2005). They showed in mice that CBD failed to
alter either food intake or locomotor activity at doses that were up to
10-fold greater than those of Δ9-THC. Although there was a trend,
Riedel et al. (2009) have also recently failed to show a signiﬁcant
hypophagic effect of CBD (10 mg/kg) in mice.
CBD, however, was able to prevent the hyperphagic effects of the
CB1 receptor agonist WIN55,212-2. CBD has been shown to interfere
with several effects mediated by CB1 receptor agonists or partial
agonists such as THC (Carlini et al., 1970; Karniol and Carlini, 1973;
Zuardi et al., 1981). In the same studywhere CBD failed to change food
intake by itself, it showed synergic effects with a Cannabis extract
containing mainly the phytocannabinoid Δ9-tetrahydrocannabivarin,
an effect that has been attributed to a CBD-induced block of residual
THC contained in the extract (Riedel et al., 2009). A recent clinical
study showed that smokers of high CBD:THC strains presented
reduced attentional bias to drug and food stimuli compared with
smokers of low CBD:THC (Morgan et al., 2010). The authors explained
this ﬁnding by a possible antagonistic or inverse agonistic property of
CBD at CB1 receptors (Pertwee, 2008).
Although the effects of Δ9-THC have been proposed to be
mediated by a partial agonism at central CB1 receptors (Pertwee,
2008), the precise molecular mechanism of action of CBD is unclear
and may involve a wide variety of mechanisms (Izzo et al., 2009;
Mechoulam et al., 2007). In spite of its low afﬁnity for CB1 and CB2Fig. 3. Effects of systemic injection of vehicle+vehicle (veh, n=5), vehicle+8-OH-
DPAT (1 mg/kg, n=5), CBD (20 mg/kg)+vehicle (n=5), CBD (20 mg/kg)+8-OH-
DPAT (1 mg/kg, n=5), on food intake (g) by fed or fasted rats. Columns represent the
means and bars represent the SEM, *pb0.0001 compared to respective vehicle+
vehicle group; #pb0.0001 compared to respective vehicle+8-OH-DPAT group.receptors, CBD is capable of antagonizing CB1/CB2 receptor agonists at
reasonably low concentrations (Thomas et al., 2007). It is also able to
antagonize, at low concentrations, the new putative cannabinoid
receptor GPR55 (Ryberg et al., 2007). Finally, CBD can block
anandamide uptake and inhibit its enzymatic hydrolysis (Bisogno,
2008).
We also evaluated the effects of CBD over another drug capable of
causing hyperphagia in rats, the serotoninergic agonist 8-OH-DPAT.
Serotonin (5-HT) plays an important role in the control of feeding
behavior (Blundell, 1977, 1984; Simansky, 1996). 5-HT acts at a
number of different receptor subtypes (Hoyer et al., 2002) and it
has been generally found that drugs that are agonists at thesemultiple
5-HT receptors decrease food intake (Blundell, 1984). The 5-HT1A
receptor agonist 8-OH-DPAT, however, has been shown to produce
hyperphagia in fed rats (Dourish et al., 1985; Ebenezer, 1992). Similar
effects on food intake were obtained with other 5-HT1A receptor
agonists, such as buspirone and gepirone (Ebenezer and Parrott, 1993;
Fletcher and Davies, 1990; Gilbert and Dourish, 1987). The mecha-
nism by which these 5-HT1A receptor agonists increase feeding has
been the subject of much research. Electrophysiological, neurochem-
ical, and behavioral studies have suggested that they act at 5-HT1A
somatodendritic autoreceptors in the raphe nuclei to decrease 5-HT
function in the central nervous system (Bendotti and Samanin, 1986;
Hjorth and Magnusson, 1988; Sharp et al., 1990; Sprouse and
Aghajanian, 1987). Thus, their mechanism of action remains consis-
tent with the putative inhibitory role of 5-HT in the control of
ingestive behavior. CBD can act as a 5-HT1A receptor agonist (Bisogno,
2008) and this mechanism has been related to several effects
mediated by this drug, such as anxiolytic and antidepressant effects
(Campos and Guimaraes, 2008; Zanelati et al., 2010). Considering this,
the inhibitory effect on 8-OH-DPAT-induced hyperphagia is somehow
surprising. It is possible, however, that CBD is producing its effect on
food intake by acting, at these doses, at post-synaptic 5-HT1A
receptors (Campos and Guimaraes, 2008) or by a different mecha-
nism. For example, several studies have demonstrated that cannabi-
noids modulate the synthesis, release and turnover of 5-HT in the
projection areas of the dorsal raphe nucleus (Egashira et al., 2002;
Nakazi et al., 2000; Sagredo et al., 2006; Tzavara et al., 2003). By
antagonizing CB1-mediated inhibitory action on serotonin release,
CBD could be reversing the consequences of decreasing 5-HT neuronal
activity by 5-HT1A agonists.
Food intake was evaluated for only 1 h and without allowing for
concomitant water ingestion. While this latter condition does not
seem to conform to normal eating behavior, several studies in the
literature have used a similar protocol (Higgs et al., 2005; Kittner
et al., 2006; Petrovich et al., 2007; Scopinho et al., 2008). CBD,
however, was only effective when food intake was pharmacologically
stimulated. Therefore, even though both the cannabinoid and
serotoninergic systems have been related to food intake control, the
present results do not allow for a conclusion on the usefulness of this
drug for treating eating disorders. Further studies, addressing those
limitations (duration of the drug effect, effects in animals allowed to
freely drink during the test) as well as investigating CBD effects on
other hyperphagic stimuli and situations need to be performed.
Even so, the present results, by suggesting that CBD can speciﬁcally
attenuate the hyperphagic stimulus of CB1 or 5HT1A agonists, could
indicate another potential clinical use of this drug. This is particularly
important considering that the CB1 receptor antagonist, rimonabant,
an effective drug in reducing the desire to eat in humans that was
being employed as a therapeutic agent for the treatment of obesity
(Christensen et al., 2007), was recently withdrawn from clinical use
because of collateral effects such as depression and anxiety (Taylor,
2009). CBD, on the other hand, is devoid of these side effects. On the
contrary, pre-clinical and clinical ﬁndings suggest that it has
anxiolytic and antidepressant properties (Guimaraes et al., 1990;
Zanelati et al., 2010).
271A.A. Scopinho et al. / Pharmacology, Biochemistry and Behavior 98 (2011) 268–272In conclusion, the present results indicate that CBD, although not
decreasing food intake by itself, can prevent the hyperphagic effects of
CB1 and 5-HT1A receptor agonists. Since this drug apparently lacks
the side-effects previously reported with the CB1 receptor antagonist
rimonabant, it could be useful for the treatment of eating disorders.
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